BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29133367)

  • 1. Regulatory T-cell Genes Drive Altered Immune Microenvironment in Adult Solid Cancers and Allow for Immune Contextual Patient Subtyping.
    Brouwer-Visser J; Cheng WY; Bauer-Mehren A; Maisel D; Lechner K; Andersson E; Dudley JT; Milletti F
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):103-112. PubMed ID: 29133367
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
    Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
    Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Altered Treg and IL-1A Expression in the Immune Microenvironment 
of Lung Squamous-cell Cancer after EGFR Blockade].
    He H; Qi L; Hou Y
    Zhongguo Fei Ai Za Zhi; 2017 Mar; 20(3):143-148. PubMed ID: 28302215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
    Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
    Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
    Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
    J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
    Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
    Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cells in gastrointestinal tumors.
    Raghavan S; Quiding-Järbrink M
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):489-501. PubMed ID: 21780896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.
    Chaudhary B; Abd Al Samid M; al-Ramadi BK; Elkord E
    Expert Opin Biol Ther; 2014 Jul; 14(7):931-45. PubMed ID: 24661020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma.
    Shen X; Li N; Li H; Zhang T; Wang F; Li Q
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1745-54. PubMed ID: 20221638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased tumor-infiltrating CD45RA
    Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
    Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
    Saito T; Nishikawa H; Wada H; Nagano Y; Sugiyama D; Atarashi K; Maeda Y; Hamaguchi M; Ohkura N; Sato E; Nagase H; Nishimura J; Yamamoto H; Takiguchi S; Tanoue T; Suda W; Morita H; Hattori M; Honda K; Mori M; Doki Y; Sakaguchi S
    Nat Med; 2016 Jun; 22(6):679-84. PubMed ID: 27111280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion.
    Ma Q; Zhao M; Wei X; Zhao J; Yang T; Zhang Q; Wang K; Yang X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Feb; 39(1):128-132. PubMed ID: 28270295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the notch signalling pathway are associated with enhanced anti-tumour immunity in colorectal cancer.
    Wang F; Long J; Li L; Zhao ZB; Wei F; Yao Y; Qiu WJ; Wu ZX; Luo QQ; Liu W; Quan YB; Lian ZX; Cao J
    J Cell Mol Med; 2020 Oct; 24(20):12176-12187. PubMed ID: 32924269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
    Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
    Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
    Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients.
    Girardin A; McCall J; Black MA; Edwards F; Phillips V; Taylor ES; Reeve AE; Kemp RA
    Int J Cancer; 2013 Apr; 132(8):1842-50. PubMed ID: 23002055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability.
    Michel S; Benner A; Tariverdian M; Wentzensen N; Hoefler P; Pommerencke T; Grabe N; von Knebel Doeberitz M; Kloor M
    Br J Cancer; 2008 Dec; 99(11):1867-73. PubMed ID: 18985040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
    Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
    Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.
    Munn DH; Sharma MD; Johnson TS
    Cancer Res; 2018 Sep; 78(18):5191-5199. PubMed ID: 30181177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.